Endocrine therapy of breast cancer

Current Medicinal Chemistry

Volumn 18, Issue 4, 2011, Pages 513-522

  Lumachi, F ^a   Luisetto, G ^a   Basso, S M M ^b   Basso, U ^c   Brunello, A ^c   Camozzi, V ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Chemoprevention; Endocrine therapy; Raloxifene; SERM; Tamoxifen

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; ALITRETINOIN; ANASTROZOLE; BARDOXOLONE; BEVACIZUMAB; BEXAROTENE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CLODRONIC ACID; DENOSUMAB; EXEMESTANE; FULVESTRANT; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; LETROZOLE; PIOGLITAZONE; RALOXIFENE; RESVERATROL; RISEDRONIC ACID; ROFECOXIB; ROSIGLITAZONE; TAMOXIFEN; TOSYLARGININE METHYL ESTER; VORINOSTAT; ZOLEDRONIC ACID;

ALCOHOLISM; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CHEMOPROPHYLAXIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EXERCISE; FEMALE; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; LOADING DRUG DOSE; LOW FAT DIET; MONOTHERAPY; ORAL CONTRACEPTION; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; POSTMENOPAUSE; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; WEIGHT CONTROL;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; RANK LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79851471023     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480177     Document Type: Article

References (99)

1. Basso, U.; Fratino, L.; Brunello, A.; Lumachi, F.; De Salvo, G. L.; Lonardi, S., Ghiotto, C.; Koussis, H.; Pasetto, L. M.; Monfardini, S. Which benefit from adding gemcitabine to vinorelbine in elderly (≥ 70 years) women with metastatic breast cancer? Early interruption of a phase II study. Ann. Oncol, 2007, 18, 58-63. (Pubitemid 46152500)
2. Lumachi, F.; Basso S. M. M.; Basso, U. Breast cancer recurrence: role of serum tumor markers CEA and CA 15-3. In Methods of Cancer Diagnosis, Therapy, and Prognosis; Hayat, M. A., Ed.; Springer: Heidelberg, 2008; Vol. 1, pp. 109-115.
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, CA Cancer J. Clin., 2009, 59, 225-49.
4. Müller, D.; Köhler, G.; Ohlinger, R. Staging procedures in primary breast cancer. Anticancer Res., 2008, 28, 2397-2400.
5. Lumachi, F.; Basso, S. M. M. Serum tumor markers in patients with breast cancer. Expert Rev. Anticancer Ther, 2004, 4, 921-31. (Pubitemid 39359875)
6. Zheng, B. Breast cancer: computer-aided detection. In Methods of Cancer Diagnosis, Therapy, and Prognosis, Hayat, M. A., Ed.; Springer: Heidelberg, 2008; Vol. 1, pp. 5-27.
7. Kulendran, M.; Salhab, M.; Mokbel, K. Oestrogen-synthesising enzymes and breast cancer. Anticancer Res., 2009, 29, 1095-1109.
8. Chen, W. Y.; Hankinson, S. E.; Schnitt, S. J.; Rosner, B. A.; Holmes, M. D.; Colditz, G. A. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer, 2004, 101, 1490-1500. (Pubitemid 39318893)
9. Lumachi, F.; Ermani, M.; Marino, F.; Di Cristofaro, L.; Tombolan, V.; Brunello, A.; Roma, A.; Basso, U. Relationship between oral contraceptive therapy and estrogen receptor status in patients with breast cancer. Anticancer Res., 2008, 28, 491-93. (Pubitemid 351362858)
10. Puhalla, S.; Brufsky, A.; Davidson, N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast, 2009, 18S3, S122-S130.
11. Larionov, A. A.; Miller, W. R. Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncol., 2009, 5, 1415-28.
12. Kelloff, G. J.; Lippman, S. M.; Dannenberg, A. J.; Sigman, C. C.; Pearce, H. R.; Reid, B. J.; Szabo, E.; Jordan, C.; Spitz, M. R.; Mills, G. B.; Papadimitrakopoulou, V. A.; Lotan, R.; Aggarwal, B. B.; Bresalier, R. S.; Kim, J.; Arun, B.; Lu, K. H.; Thomas, M. E.; Rhodes, H. E.; Brewer, M. A.; Follen, M.; Shin, D. M.; Parnes, H. L.; Siegfried, J. M.; Evans, A. A.; Blot, W. J.; Chow, W.-H.; Blount, P. L.; Maley, C. C.; Wang, K. K.; Lam, S.; Lee, J. J.; Dubinett, S. B.; Engstrom, P. F.; Meyskens, F. L. Jr.; O'Shaughnessy, Y.; Hawk, E. T.; Levin, B.; Nelson, W. G.; Hong, W. K. for the AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer. A plan to move forward. Clin. Cancer Res., 2006, 12, 3661-97. (Pubitemid 44000248)
13. Gonzales-Angulo, A. M.; Morales-Vasquez, F.; Hortobagyi, G. N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol., 2007, 608, 1-22.
14. Lippman, S. M.; Hong, W. K. Cancer prevention science and practice. Cancer. Res., 2002, 62, 5119-25. (Pubitemid 35024578)
15. O'Shaughnessy, J. A.; Kelloff, G. J.; Gordon, G. B.; Dannenberg, A. J.; Hong, W. K.; Fabian, C. J.; Sigman, C. C.; Bertagnolli, M. M.; Stratton, S. P.; Lam, S.; Nelson, W. G.; Meyskens, F. L.; Alberts, D. S.; Follen, M.; Rustgi, A. K.; Papadimitrakopoulou, V.; Scardino, P. T.; Gazdar, A. F.; Wattenberg, L. W.; Sporn, M. B.; Sakr, W. A.; Lippman, S. M.; Von Hoff, D. D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res., 2002, 8, 314-46.
16. Howell, A. The endocrine prevention of breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2008, 22, 615-23.
17. Blaha, P.; Dubsky, P.; Fitzal, F.; Bachleitner-Hofmann, T.; Jakesz, R.; Gnant, M.; Steger, G. Breast cancer chemoprevention - a vision not yet realized. Eur. J. Cancer Care, 2009, 18, 438-46.
18. Lumachi, F.; Ermani, M.; Basso, S. M. M.; Lonardi, S.; Tosoni, A.; Brandes, A. A. Breast cancer risk in symptomatic women spontaneously undergoing clinical breast examination. Anticancer Res., 2003, 23, 3565-68. (Pubitemid 36975467)
19. Thomsen, A.; Kolesar, J. M. Chemoprevention of breast cancer. Am. J. Health Syst. Pharm., 2008, 65, 2221-28.
20. Lumachi, F.; Frigo, A. C.; Basso, U.; Tombolan, V. Ermani, M. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause, 2010, 17, 524-28.
21. Armstrong, K.; Eisen, A.; Weber, B. Assessing the risk of breast cancer. N. Engl. J. Med., 2000, 342, 564-71. (Pubitemid 30117898)
22. Lumachi F.; Ermani, M.; Brandes, A. A.; Basso, U.; Paris, M.; Basso, S. M. M.; Boccagni, P. Breast cancer risk in healthy and symptomatic women: results of a multivariate analysis. A casecontrol study. Biomed. Parmacother. 2002, 56, 416-20. (Pubitemid 35232745)
23. Puntoni, M.; Decensi, A. The rationale and potential of cancer chemoprevention with special emphasis on breast cancer. Eur. J. Cancer, 2009, 45, 346-54.
24. Gibson, L.; Lawrence, D.; Dawson, C.; Bliss, J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst. Rev., 2009, 4, CD003370.
25. Lumachi, F.; Basso, S. M. M.; Orlando, R. Cytokines, thyroid diseases and thyroid cancer. Cytokine, 2010, 50, 229-33.
26. Makita, H.; Mutoh, M.; Maruyama, T.; Yonemoto, K.; Kobayashi, A.; Fujitsuka, H.; Toida, M.; Shibata, T.; Miyamoto, S.; Yasui, Y.; Suzuki, R.; Wakabayashi, K.; Tanaka, T. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis, 2007, 28, 677-84. (Pubitemid 46523364)
27. Lumachi, F.; Basso, S. Apoptosis: life through planned cellular death. Regulating mechanisms, control system, and relations with thyroid disease. Thyroid, 2002, 12, 27-34. (Pubitemid 34106713)
28. Saeki, T.; Noguchi, S.; Aogi, K.; Inaji, H.; Tabei, T.; Ikeda, T. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Ann. Oncol., 2009, 20, 868-73. 2009, 20, 868-73.
29. Tomita, S.; Zhang, Z.; Nakano, M.; Ibusuki, M.; Kawazoe, T.; Yamamoto, Y.; Iwase, H. Estrogen receptor α gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci., 2009, 100, 1012-17.
30. Lumachi, F.; Basso, S. M. M.; Brandes, A. A.; Pagano, D.; Ermani, M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res., 2004, 24, 3221-24. (Pubitemid 39390976)
31. Castrellon, A. B.; Glück, S. Chemoprevention of breast cancer. Expert Rev. Anticancer Ther, 2008, 8, 443-52. (Pubitemid 351836291)
32. Dunn, B. K.; Ryan, A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators. Ann. N. Y. Acad. Sci., 2009, 1155, 141-61.
33. Gail, M. H.; Brinton, L. A.; Byar, D. P.; Corle, D. K.; Green, S. B.; Schairer, C.; Mulvihill, J. J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst, 1989, 81, 1879-86. (Pubitemid 20026073)
34. Gail, M. H.; Costantino, J. P. Validating and improving models for projecting the absolute risk of breast cancer. J. Natl. Cancer Inst, 2001, 93, 334-5. (Pubitemid 32229370)
35. MacKarem G.; Roche, C. A.; Hughes, K. S. The effectiveness of the gail model in estimating risk for development of breast cancer in women under 40 years of age. Breast J., 2001, 7, 34-9. (Pubitemid 32162845)
36. Novotny, J.; Pecen, L.; Petruzelka, L.; Svobodnik, A.; Dusek, L.; Danes, J.; Skovajsova M. Breast cancer risk assessment in the Czech female population - an adjustment of the original Gail model. Breast Cancer Res. Treat., 2006, 95, 29-35. (Pubitemid 43228079)
37. Powles, T. J.; Ashley, S.; Tidy, A.; Smith, I. E.; Dowsett, M. Twenty-year follow-up of the royal marsden randomized, doubleblinded tamoxifen breast cancer prevention trial. J. Natl. Cancer Inst, 2007, 99, 283-90. (Pubitemid 47073491)
38. Veronesi, U.; Maisonneuve, P.; Rotmensz, N.; Bonanni, B.; Boyle, P.; Viale, G.; Costa, A.; Sacchini, V.; Travaglini, R.; D'Aiuto, G.; Oliviero, P.; Lovison, F.; Gucciardo, G.; Del Turco, M. R.; Muraca, M. G.; Pizzichetta, M. A.; Conforti, S.; Decensi, A.; Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J. Natl. Cancer Inst, 2007, 99, 727-37. (Pubitemid 47073533)
39. Cuzick, J.; Powels, T.; Veronesi, U.; Forbes, J.; Edwards, R.; Ashley, S.; Boyle, P. Overview of the main outcomes in breast cancer prevention trials. Lancet, 2003, 361, 296-300. (Pubitemid 36126189)
40. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Cecchini, R. S.; Cronin, W. M.; Robidoux, A.; Bevers, T. B.; Kavanah, M. T.; Atkins, J.; Margolese, R. G., Runowicz, CD.; James, J. M.; Ford, L. G.; Wolmark, N. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst, 2005, 97, 1652-62. (Pubitemid 41672231)
41. Jolly, E. E.; Bjarnason, N. H.; Never, P.; Plouffe, L. Jr.; Johnston, C. C. Jr.; Watts, S. D.; Arnaud, C.D.; Mason, T. M.; Crans, G.; Akers, R.; Draper, M. W. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause, 2003, 10, 337-44. (Pubitemid 36870506)
42. Cauley, J. A.; Norton, L.; Lippman, M. E.; Eckert, S.; Krueger, K. A.; Purdie, D. W.; Farrerons, J.; Karasik, A.; Mellstrom, D.; Ng, K. W.; Stepan, J. J.; Powles, T. J.; Morrow, M.; Costa A.; Silfen, S. L.; Walls, E. L.; Schmitt, H.; Muchmore, D. B.; Jordan, V. C.; Ste-Marie, L. G. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001, 65, 125-34. (Pubitemid 32193616)
43. Martino, S.; Cauley, J. A.; Barrett-Connor, E.; Powels, T. J.; Mershon, J.; Disch, D.; Secrest, R. J.; Cummings, S. R; for the CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl. Cancer Inst., 2004, 96, 1751-61. (Pubitemid 39654569)
44. Vogel, V. G.; Costantino, J. P; Wickerham, D. L.; Cronin, W. M.; Cecchini, R. S.; Atkins, J. N.; Bevers, T. B.; Fehrenbacher, L.; Pajon, E. R. Jr.; Wade, J. L. 3rd; Robidoux, A.; Margolese, R. G.; James, J.; Lippman, S. M.; Runowicz, CD.; Ganz, PA.; Reis, S. E.; McCaskill-Stevens, W.; Ford, L. G.; Jordan, V. C.; Wolmark. N; National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295, 2727-41.
45. Geisler, J.; Helle, H.; Ekse, D.; Duong, N. K.; Evans, D. B.; Nordbø, Y.; Aas, T.; Lønning, P. E. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin. Cancer Res., 2008, 14, 6330-6335.
46. Addo, S.; Yates, R. A.; Laight, A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer, 2002, 87, 1354-59. (Pubitemid 36044307)
47. Wakeling, A. E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr. Relat. Cancer, 2000, 7, 17-28. (Pubitemid 30305868)
48. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15-year survival: an overview of the randomized trials. Lancet, 2005, 365, 1687-1717.
49. Goldhirsch, A.; Ingle, J. N.; Gelber, R. D.; Coates, A. S.; Thürlimann, B.; Senn, H. J.; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann. Oncol., 2009, 20, 1319-29.
50. Arimidex, Tamoxifen, alone or in combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100 month analysis of the ATAC trial. Lancet, 2008, 9, 45-53.
51. Coates, A. S.; Keshaviah, A.; Thurliman, B.; Mouridsen, H.; Mauriac, L.; Forbes, J. F.; Paridaens, R.; Castiglione-Gersch, M.; Gelber, R. D.; Colleoni, M.; Lang, I.; Del Mastro, L.; Smith, I.; Chirgwin, J.; Novaret, J. M.; Pienkowski, T.; Wardley, A.; Jakobsen, E. H.; Price, K. N.; Goldhirsch, A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol., 2007, 25, 486-92. (Pubitemid 350002953)
52. Coombes, R. C.; Kilburn, L. S.; Snowdon, C. F.; Paridaens, R.; Coleman, R. E.; Jones, S. E.; Jassem, J.; Van de Velde, C. J.; Delozier, T.; Alvarez, I.; Del Mastro, L.; Ormann, O.; Diedrich, D.; Coates, A. S.; Bajetta, E.; Holmberg, S. B.; Dodwell, D.; Mickiewicz, E.; Andersen, J.; Lonning, P. E.; Cocconi, G.; Forbes, J.; Castiglione, M.; Stuart, N.; Stewart, A.; Bertelli, G.; Hall, E.; Bogle, R. G.; Carpentieri, M.; Colajori, E.; Subar, M.; Ireland, E.; Bliss, J. M.; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet, 2007, 369, 559-70.
53. Jakesz R.; Janat W.; Gnant M.; Mittleboeck M.; Greil R.; Tausch C.; Hilfrich J.; Kwasny W.; Menzel C.; Samonigg H.; Seifert M.; Gademann G.; Kaufmann M.; Wolfagang J.; ABCSG and the GABG. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 2005, 366, 455-62. (Pubitemid 41111693)
54. Boccardo, F.; Rubagotti, A.; Guglielimini, P.; Fini, A.; Paladini, G.; Mesiti, M.; Rinaldini, M.; Scali, S.; Porpiglia, M.; Benedetto, C.; Restuccia, N.; Buzzi, F.; Franchi, R.; Massidda, B.; Distante, V.; Amadori, D.; Sismondi, P. Switching to anastrozole versus continued tamoxifen treament of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann. Oncol., 2006, 17 (S7), vii 10-14.
55. Goss, P.; Ingle, J. N.; Martino S.; Robert, N. J.; Muss, H. B.; Piccart, M. J., Castiglione, M, Tu D, Shepherd, L. E.; Pritchard, K. I.; Livingston, R. B.; Davidson, N. E.; Norton, L.; Perez, E. A.; Abrams J. S.; Cameron D. A.; Palmer, M. J.; Pater J. L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: Updated findings form NCIC CTC MA 17. J. Natl. Cancer Inst., 2005, 97, 1262-71. (Pubitemid 41535367)
56. The BIG Collaborative Group. Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. N. Engl. J. Med., 2009, 361, 766-76.
57. Rasmussen, B. B.; Regan, M. M.; Lykkesfeldt, A. E.; Dell'Orto, P.; Del Curto, B.; Henriksen, K. L.; Mastropasqua, M. G.; Price, K. N.; Méry, E.; Lacroix-Triki, M.; Braye, S.; Altermatt, H. J.; Gelber, R. D.; Castiglione-Gertsch, M.; Goldhirsch, A.; Gusterson, B. A.; Thürlimann, B.; Coates, A. S.; Viale, G.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol., 2008, 9, 23-8.
58. Viale, G.; Maiorano, E.; Mastropasqua, M. G.; Dell'Orto, P.; Rasmussen, B. B.; Raffoul, J.; Neven, P.; Orosz, Z.; Braye, S.; Ohlschlegel, C.; Thurlimann, B.; Gelber, R. D.; Castiglione-Gertsch, M.; Price, K. N.; Goldhirsch, A.; Gusterson, B. A.; Coates, A. S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomised trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J. Clin. Oncol., 2007, 25, 3846-52. (Pubitemid 47477259)
59. Dowsett, M.; Cuzick, J.; Ingle, J.; Coates, A.; Forbes, J.; Bliss, J.; Buyse, M.; Baum, M.; Buzdar, A.; Colleoni, M.; Coombes, C.; Snowdon, C.; Gnant, M.; Jakesz, R.; Kaufmann, M.; Boccardo, F.; Godwin, J.; Davies, C.; Peto, R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol., 2010, 28, 509-18.
60. Paridaens, R. J.; Dirix, L. Y.; Beex, L. V.; Nooij, M.; Cameron, D. A.; Cufer, T.; Piccart, M. J.; Bogaerts, J.; Therasse. P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J. Clin. Oncol., 2008, 20, 4883-90.
61. Nabholtz, J. M.; Moure-Reynier, M. A.; Durando, X.; Van Praagh, I.; Al-Sukhun, S.; Ferriere, J. P.; Chollet, P. Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer. Expert Opin. Pharmacother., 2009, 10, 1435-47.
62. Hind D.; Ward S.; De Nigris E.; Simpson E.; Carroll C.; Wyld, L. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol. Assess., 2007, 11, iii-iv, ixxi, 1-134.
63. Risebrough, N. A.; Verma, S.; Trudeau, M.; Mittmann, N. Costeffectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer, 2007, 110, 499-508. (Pubitemid 47106137)
64. Annemans, L. Methodological issues in evaluating cost effectiveness of adjuvant Aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making. Pharmacoeconomics, 2008, 26, 409-23. (Pubitemid 351572053)
65. Lønning P. E. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur. J. Cancer, 2009, 45, 527-35.
66. Robertson, J. F.; Osborne, C. K.; Howell, A.; Jones, S. E.; Mauriac, L.; Ellis, M.; Kleeberg, U. R.; Come, S. E.; Vergote, I.; Gertler, S.; Buzdar, A.; Webster, A.; Morris, C. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer, 2003, 98, 229-238. (Pubitemid 36828445)
67. Howell, A.; Pippen, J.; Elledge, R. M.; Mauriac, L.; Vergote, I.; Jones, S. E.; Come, S. E.; Osborne, C. K.; Robertson, J. F. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer, 2005, 104, 236-39. (Pubitemid 40993248)
68. Chia, S.; Gradishar, W.; Mauriac, L.; Bines, J.; Amant, F.; Federico, M.; Fein, L.; Romieu, G.; Buzdar, A.; Robertson, J. F.; Brufsky, A.; Possinger, K.; Rennie, P.; Sapunar, F.; Lowe, E.; Piccart, M. Double-blind, randomized placebo-controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptorpositive advanced breast cancer: Results from EFECT. J. Clin. Oncol., 2008, 26, 1664-70.
69. Robertson, J. F. R. Fulvestrant (Faslodex) - How to make a good drug better. Oncologist, 2007, 12, 774-84. (Pubitemid 47328221)
70. Robertson, J. F; Llombart-Cussac, A.; Rolski, J.; Feltl, D.; Dewar, J.; Macpherson, E.; Lindemann, J.; Ellis, M. J. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol., 2009, 27, 4530-35.
71. Baum, M.; Buzdar, A.; Cuzick, J.; Forbes, J.; Houghton, J.; Howell, A.; Sahmoud, T.; The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 2003, 98, 1802-10. (Pubitemid 37310221)
72. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann, B.; Keshaviah A.; Coates, AS.; Mouridsen, H.; Mauriac, L.; Forbes, J. F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R. D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K. N.; Goldhirsch, A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 2005, 353, 2747-57. (Pubitemid 43016814)
73. Camozzi, V.; Lumachi, F.; Mantero, F.; Piccolo, M.; Luisetto, G. Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status. Osteoporosis. Internat., 2003, 14, 602-08. (Pubitemid 36980586)
74. Lumachi F.; Camozzi, V.; Ermani, M.; De Lotto F.; Luisetto, G. Bone mineral density improvement after successful parathyroidectomy in pre-and postmenopausal women with primary hyperparathyroidism: a prospective study. Ann. N. Y. Acad. Sci., 2007, 1117, 357-61. (Pubitemid 350191265)
75. Coombes, R. C.; Hall, E.; Gibson, L. J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S. E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A. S.; Bajetta, E.; Dodwell, D.; Coleman, R. E.; Fallowfield, L.; Mickiewicz, E.; Andersen, J.; Lønning, P. E.; Cocconi, G.; Stewart, A.; Stuart N.; Snowdon C. F.; Carpentieri, M.; Massimini, G.; Bliss, J. M.; van de Velde, C.; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med., 2004, 350, 1081-92. (Pubitemid 38298988)
76. McCloskey, E. Effects of third-generation aromatase inhibitors on bone. Eur. J. Cancer, 2006, 42, 1044-51.
77. Reid, D. M.; Doughty, J.; Eastell, R.; Heys S. D.; Howell, A.; McCloskey, E. V.; Powles, T.; Selby, P.; Coleman, R. E. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev., 2008, 34 (S1), S3-S18.
78. Writing Group for the ISCD Position Development Conference. Indications and reporting for dual-energy x-ray absorptiometry. J. Clin. Densitom., 2004, 7, 37-44.
79. Hadji P.; Body JJ.; Aapro M. S.; Brufsky, A.; Coleman, R. E.; Guise, T.; Lipton, A.; Tubiana-Hulin, M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol., 2008, 19, 1407-16.
80. Hadji, P.; Ziller, M.; Albert, US.; Kalder, M. Assessment of fracture risk in women with breast cancer using current vs. emerging guidelines. Br. J. Cancer, 2010, 102, 645-50.
81. Hillner, B. E.; Ingle, J. N.; Chlebowski, R. T.; Gralow, J.; Yee, G. C.; Janjan, N. A.; Cauley, J. A.; Blumenstein, B. A.; Albain, K. S.; Lipton, A.; Brown, S.; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol., 2003, 21, 4042-57. (Pubitemid 46606220)
82. Coleman RE. Bisphosphonates: clinical experience. Oncologist, 2004, 9 (S4), 14-27. (Pubitemid 39363165)
83. Devitt, B.; McLachlan, S. A. Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther. Clin. Risk Manag., 2008, 4, 453-58. (Pubitemid 351712003)
84. Van Poznak, C.; Hannon, R. A.; Mackey, J. R.; Campone, M.; Apffelstaedt, J. P.; Clack, G.; Barlow, D.; Makris, A.; Eastell, R. Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial. J. Clin. Oncol., 2010, 28, 967-75.
85. Gnant, MF.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Grampp, S.; Kaessmann, H.; Schmid, M.; Menzel, C.; Piswanger-Soelkner, JC.; Galid, A.; Mittlboeck, M.; Hausmaninger, H.; Jakesz, R.; Austrian Breast and Colorectal Cancer Study Group. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol., 2007, 25, 820-28. (Pubitemid 350002882)
86. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rücklinger, E.; Greil, R.; ABCSG-12 Trial Investigators.; Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med., 2009, 360, 679-91.
87. Brufsky A.; Harker W. G.; Beck J. T.; Carroll R.; Tan-Chiu E.; Seidler C.; Hohneker J.; Lacerna L.; Petrone S.; Perez E. A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol., 2007, 25, 829-36. (Pubitemid 350002883)
88. Theriault, R. L. Bisphosphonates: ready for use as adjuvant therapy of breast cancer? Curr. Opin. Obstet. Gynecol., 2010, 22, 61-6.
89. Mahtani, R.; Jahanzeb, M. Bisphosphonates as anticancer therapy for early breast cancer. Clin. Breast Cancer, 2010, 10, 359-66.
90. Camozzi, V.; Franzin, C.; Luisetto, G. Medical treatment of hypercalcemia. In Hypercalcemia. Pathophysiology & Treatment; Lumachi, F.; Basso, S. M. M., Eds; Bentham Science Publishers Ltd.: Sharjah, U. A. E., 2010, pp. 88-99.
91. Hoff, A. O.; Toth, B. B.; Altundag, K.; Johnson, M. M.; Warneke, C. L.; Hu, M.; Nooka, A.; Sayegh, G.; Guarneri, V.; Desrouleaux, K.; Cui, J.; Adamus, A.; Gagel, R. F.; Hortobagyi, G. N. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res., 2008, 23, 826-36. (Pubitemid 351768801)
92. Lumachi, F.; Brunello, A.; Roma, A.; Basso, U. Cancer-induced hypercalcemia. Anticancer Res., 2009, 29, 1551-55.
93. Fizazi, K.; Lipton, A.; Mariette, X.; Body, J. J.; Rahim, Y.; Gralow, J.R.; Gao, G.; Wu, L.; Sohn, W.; Jun, S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol., 2009, 27, 1564-71.
94. Ellis, G. K.; Bone, H. G.; Chlebowski, R.; Paul, D.; Spadafora, S.; Fan, M.; Kim, D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res. Treat., 2009, 118, 81-7.
95. Lumachi, F.; Brunello, A.; Roma, A.; Basso, U. Medical treatment of malignancy-associated hypercalcemia. Curr. Med. Chem., 2008, 15, 415-21. (Pubitemid 351266947)
96. Lee, W. L.; Chao H. T.; Cheng, M. H., Wang, P. H. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Maturitas, 2008, 60, 92-107.
97. Jordan, V. G. Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study for Tamoxifene and Raloxifene (STAR) Trial. Eur. J. Cancer, 2006, 42, 2909-13.
98. Temin, S. American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Gynecol. Oncol., 2009, 115, 132-4.
99. Jordan, V. C.; Lewis-Wambaj, J. S.; Patel, R. R.; Kim, H.; Ariazi, E. A. New hypothesis and opportunities in endocrine therapy: amplification of estrogen-induced apoptosis. Breast, 2009, 18 (S3), S10-S17.